Protalix BioTherapeutics (PLX) Current Assets (2010 - 2026)

Protalix BioTherapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $86.4 million for Q1 2026.

• On a quarterly basis, Current Assets rose 42.7% year-over-year to $86.4 million in Q1 2026; TTM through Mar 2026 was $86.4 million, a 42.7% increase from a year earlier, with the FY2025 full-year figure at $66.7 million, up 10.98% from the prior year.
• Current Assets grew to $86.4 million in Q1 2026 per PLX's latest filing, from $66.7 million in the prior quarter.
• Across five years, Current Assets topped out at $86.4 million in Q1 2026 and bottomed at $44.9 million in Q4 2022.
• The 5-year median for Current Assets is $65.5 million (2025), against an average of $63.2 million.
• Across the five-year window, Current Assets tumbled 48.19% in 2022 and surged 58.69% in 2023, its largest moves.
• Year by year, Current Assets stood at $44.9 million in 2022, then soared by 55.82% to $69.9 million in 2023, then slipped by 14.09% to $60.1 million in 2024, then increased by 10.98% to $66.7 million in 2025, then rose by 29.52% to $86.4 million in 2026.
• Per Business Quant, the three latest PLX Current Assets figures stand at $86.4 million (Q1 2026), $66.7 million (Q4 2025), and $66.5 million (Q3 2025).